LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States

Core Insights - LENZ Therapeutics has launched VIZZ, the first FDA-approved aceclidine-based eye drop for presbyopia, which is expected to improve near vision for up to 10 hours in adults [1][2][10] - VIZZ is set to be commercially available to consumers starting in October 2025, with broader availability anticipated by mid-Q4 2025 [1][10] - Presbyopia affects approximately 128 million adults in the United States, highlighting a significant market opportunity for VIZZ [1][10] Product Details - VIZZ (aceclidine ophthalmic solution) 1.44% is designed to restore clear near vision for up to 10 hours and is preservative-free, provided in single-dose vials [5][10] - The mechanism of action involves a predominantly pupil-selective miotic effect, contracting the iris sphincter muscle to create a pinhole effect that enhances depth of focus without causing a myopic shift [2][5] - In the CLARITY Phase 3 clinical trial, 93% of participants achieved 20/40 or better near vision within 30 minutes of application [2] Market Context - Presbyopia is a common age-related condition that affects nearly all individuals over the age of 45, with adults over 50 losing an average of 1.5 lines of near vision every six years [4][10] - The condition is typically self-managed with over-the-counter reading glasses, but VIZZ offers a new prescription option for improved near vision [4][10] - The global market for presbyopia treatments is substantial, with an estimated 1.8 billion people affected worldwide [10]